KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2129-2134

  Akiyoshi, Kohei ^a   Yamada, Yasuhide ^a   Honma, Yoshitaka ^a   Iwasa, Satoru ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Shimada, Yasuhiro ^a   Taniguchi, Hirokazu ^a   Furuta, Koh ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cetuximab; Colorectal cancer; HRMA; KRAS mutation; Sequencing

Indexed keywords

CETUXIMAB; IRINOTECAN; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL EVALUATION; COLORECTAL CANCER; DISEASE CONTROL; DNA EXTRACTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; WILD TYPE;

CETUXIMAB; COLORECTAL CANCER; HRMA; KRAS MUTATION; SEQUENCING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FOLLOW-UP STUDIES; FREEZING; HUMANS; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84878173533     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN Database. Japan: Summary statistics. 2010. Available at: GLOBOCAN 2010. http://globocan.iarc.fr/
3. Bokemeyer C, Van Cutsem E, Rougier P et al: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48: 1466-1475, 2012.
4. Van Cutsem E, Kohne CH, Lang I et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019, 2011.
5. Allegra CJ, Jessup JM, Somerfield MR et al: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096, 2009.
6. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. 2013: Version 3.2013.
7. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG and Pryor RJ: High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 49: 853-860, 2003. (Pubitemid 36623462)
8. Fukui T, Ohe Y, Tsuta K et al: Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting snalysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 14: 4751-4757, 2008.
9. Matsuno Y, Ohe Y, Furuta K et al: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126: 608-615, 2006. (Pubitemid 44498512)
10. Takano T, Ohe Y, Tsuta K et al: Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res 13: 5385-5390, 2007. (Pubitemid 47510364)
11. Do H, Krypuy M, Mitchell PL, Fox SB and Dobrovic A: High-resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142, 2008.
12. Han CB, Li F, Ma JT and Zou HW: Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 30: 741-747, 2012.
13. Franklin WA, Haney J, Sugita M, Bemis L and Jimeno A, Messersmith WA: KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 12: 43-50, 2010.
14. Lanthaler AJ, Spizzo G, Mitterer M, Mian C and Mazzoleni G: Interlaboratory comparison of K-ras testing by real-time PCR and RFLP in colorectal cancer samples. Diagn Mol Pathol 20: 90-93, 2011.
15. Oliner K, Juan T, Suggs S et al: A comparability study of 5 commercial KRAS tests. Diagn Pathol 5: 23, 2010.
16. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A and Messersmith WA: KRAS mutation comparison of testing methods and tissue sampling techniques in colon cancer. The Journal of Molecular Diagnostics 12: 43-50, 2010.
17. Ma ESK, Wong CLP, Law FBF, Chan WK and Siu D: Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol 62: 886-891, 2009.
18. De Roock W, Jonker DJ, Di Nicolantonio F et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820, 2010.
19. Cunningham D, Humblet Y, Siena S et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)